Loading
Peroxisome Proliferator-activated Receptors · Journal article
Food Frontiers · August 18, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that systematizes current knowledge of taurine's biochemical roles and preclinical mechanisms in metabolic disease, but does not report a quantified clinical outcome or meta-analytic synthesis. The authors explicitly acknowledge that clinical translation remains limited by lack of population-based evidence and unclear dose-response relationships, positioning taurine as a hypothesis for future investigation rather than an established therapeutic.
Narrative review. Mechanistic and animal model studies; no human trial populations quantified..
Taurine acts through antioxidant, anti-inflammatory, and anti-apoptotic effects in preclinical models. Proposed mechanisms include epigenetic regulation, bile acid-mediated lipid metabolism, and gut-liver axis interactions. Preclinical studies show promising therapeutic potential in diabetes, obesity, NAFLD, atherosclerosis, tumors, aging, and metabolic disorder-related ocular and brain injury.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should regard taurine supplementation for metabolic disease as mechanistically plausible but lacking adequate human trial evidence or defined dose guidance. Current evidence does not support routine clinical adoption pending rigorous population-based studies.
This is a narrative review synthesizing preclinical evidence and mechanistic hypotheses about taurine's role in metabolic disease, without reporting original clinical trial data or meta-analytic quantification of effect.
As stated by the source record.
Clinicians should regard taurine supplementation for metabolic disease as mechanistically plausible but lacking adequate human trial evidence or defined dose guidance. Current evidence does not support routine clinical adoption pending rigorous population-based studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Taurine (Tau) is a sulfur‐containing amino acid prevalent in animal tissues and primarily acquired through dietary sources. Although previously categorized as a conditionally essential amino acid, its significant role in regulating redox balance, inflammatory responses, apoptosis, and metabolic homeostasis has garnered increasing recognition. Unlike focusing on a single disease, this article provides a comprehensive and up‐to‐date overview of the chemical properties, biological functions and supplementary safety of taurine, and particularly clarifies the protective effects and molecular mechanisms of taurine in metabolism‐related diseases such as diabetes and its complications, obesity, non‐alcoholic fatty liver disease, atherosclerosis, tumors, and aging, as well as metabolic disorder‐related ocular and brain injury. Available evidence suggests that taurine acts not only through antioxidant, anti‐inflammatory, and anti‐apoptotic effects, but may also be involved in epigenetic regulation, bile acid–mediated lipid metabolism, and inter‐organ interactions (e.g., gut‐liver axis). While preclinical studies have demonstrated promising therapeutic potential, its clinical translation is currently hindered by a paucity of population‐based evidence, ill‐defined dose‐response relationships (e.g., nonlinear characteristics in specific diseases), and its paradoxical role within specific tumor microenvironments. This article aims to provide a systematic theoretical reference for the in‐depth research and potential clinical application of taurine in the prevention and treatment of metabolic diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.